Clearmind Medicine submits three additional international patent applications

Clearmind Medicine (CMND) has submitted three additional patent applications under the international Patent Cooperation Treaty, as part of its ongoing collaboration with SciSparc Ltd. (SPRC). The patent applications refer to novel proprietary compositions of 3,4-Methylenedioxymethamphetamine, Ibogaine, and Ketamine, each with Palmitoylethanolamide, the active ingredient of SciSparc’s proprietary CannAmide. These applications were previously filed as provisional patent applications with the United States Patent and Trademark Office. Overall, as part of this collaboration, 8 other patent applications have been filed by Clearmind with the USPTO for various combinations, 3 of them for the combination of SciSparc’s PEA with Clearmind’s MEAI compound for the treatment of alcohol use disorder, treatment of cocaine addiction and treatment of obesity and its related metabolic disorders. In addition, seven patent applications were filed under the international PCT.